### Indication
- Kaposi sarcoma of unspecified primary site

### EML status history
- First added in 2015 (TRS 994)

### Therapeutic alternatives
- The recommendation is for this specific medicine

### Patent information
- Patents have expired in most jurisdictions
- Read more about patents.

### Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for paclitaxel on the complementary list of the EML for use in treatment protocols for Kaposi sarcoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee’s 2015 consideration of treatment protocols for Kaposi sarcoma is attached.